Lowering the Age to 50: How the CDC’s PCV Shift Opens a Large New Adult Patient Pool

0
2

Pneumococcal Vaccine Market size was valued at USD 9.16 billion in 2025 and is projected to grow from USD 9.61 billion in 2026 to USD 14.57 billion by 2034, exhibiting a CAGR of 5.30%, according to Polaris Market Research. Pneumococcal vaccines protect against infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, bacteremia and otitis media. They introduce safe pneumococcal antigens that prompt B and T cells to produce specific antibodies and memory cells, which respond quickly on later exposure. Rising disease incidence across all age groups and health policies that promote widespread vaccination are the main forces behind growth.

Disease burden and policy support

Childhood immunization remains the cornerstone of the Pneumococcal Vaccine Market. The World Health Organization estimates that pneumococcal disease causes roughly 1.6 million deaths each year, with 0.7 to 1 million occurring in children under five. Gavi reported in 2022 that third-dose pneumococcal conjugate vaccine (PCV3) coverage among its 57 member countries rose to 70%, up from 56% in 2019-2021. Government programs add momentum. In June 2021, Odisha introduced PCV into its universal immunization program to protect 800,000 young children, and in September 2022 Indonesia launched PCV nationwide.

Adult immunization is the second growth lever. The CDC’s Advisory Committee on Immunization Practices expanded PCV coverage by lowering the recommended age from 65 to 50 years. Adults with COPD, diabetes or heart disease face higher pneumonia risk, and clinicians increasingly rely on shared clinical decision making. Payers also see value, since prevention reduces hospitalizations, intensive care admissions and long-term antibiotic therapy compared with treating invasive infection.

Higher-valency vaccines reshape the pipeline

Product development is moving from 13-valent toward 15-, 20- and 21-valent conjugate vaccines with broader serotype coverage. Pfizer’s PREVNAR 20 was approved by the U.S. FDA in June 2021 for adults aged 18 and older. In June 2026, the FDA approved an additional indication for Merck’s 21-valent CAPVAXIVE in at-risk children and adolescents aged 2 through 17. In May 2026, Pfizer advanced its 25-valent pediatric candidate into pivotal Phase 3 after strong Phase 2 infant results. In October 2026, Vaxcyte reported that its 31-valent VAX-31 met all primary endpoints in the OPUS-1 Phase 3 trial against PCV20 and PCV21. Sanofi and SK Bioscience also began collaborating in January 2025 on next-generation PCVs targeting serotypes missing from current vaccines.

Segment leaders and fast movers

By vaccine type, the polysaccharide vaccine (PPV) led with a 54.6% revenue share in 2025 on its established use against serious infections in adults. It offers broad serotype coverage but limited immunological memory and limited effectiveness in young children. Conjugate vaccines (PCV) are projected to record the highest CAGR of 7.2% by delivering a stronger, longer-lasting immune response and wider serotype coverage. By product, Synflorix is expected to grow fastest at a 7.6% CAGR thanks to its cost-effectiveness in budget-constrained countries, while Prevnar 13 benefits from approval across infants, children and adults.

Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/pneumococcal-vaccine-market

Regional outlook

North America dominated with a 40.9% share in 2025, supported by strong healthcare infrastructure, early vaccine adoption and a growing number of FDA approvals. Asia Pacific is projected to post the highest regional CAGR of 6.8% through 2034, driven by investment in vaccine development, a rapidly expanding population and rising pneumococcal infections.

Regulatory hurdles

Stringent regulation and lengthy approval processes for new vaccines remain the primary restraint. They slow development timelines and can discourage investors from backing new candidates.

Competitive landscape

The competitive field is fragmented. R&D investment, strategic partnerships and falling PCV prices in middle-income countries are shaping how companies compete. Leading participants include GSK, Pfizer, Serum Institute of India, CSL, Sanofi, Walvax Biotechnology, Beijing Minhai Biotechnology, Johnson & Johnson, AstraZeneca and Novavax, alongside Merck.

Pneumococcal Vaccine Market growth through 2034 will hinge on how quickly next-generation conjugate vaccines reach patients and how far immunization coverage extends in emerging economies. Expanding childhood programs, lower adult eligibility ages and higher-valency launches point to steady demand, while regulatory timelines remain the key variable for developers and investors.

More Trending Latest Reports By Polaris Market Research:

Fog Computing Market

Engineering Services Outsourcing Market

Iot Microcontroller Market

ModelOPs Market

Engineering Services Outsourcing Market

Liver Cancer Market

Automatic Identification and Data Capture Market

3D Motion Capture System Market

Benign Prostatic Hyperplasia Surgical Treatment Market

Zoeken
Categorieën
Read More
Other
Custom Lead Washers and Durable Lead Flashing Solutions for Construction and Industrial Use | Nuclead Manufacturing Co Inc
Introduction Lead is a versatile industrial metal valued for its high density, malleability, and...
By nucleadmanufacturing 2026-10-23 07:03:18 0 268
Other
7 Factors That Separate Effective Digital Marketing Agencies From the Rest
    Choosing a digital marketing agency is easy. Choosing one that can genuinely...
By gary93088 2026-09-02 10:18:58 0 600
Other
Aroma Chemicals Market Size and Outlook Driven by Rising Demand for Fragrances and Flavors
Aroma chemicals are essential ingredients in fragrances, flavors, cosmetics, toiletries, and a...
By nilajadhav312 2026-10-01 10:45:28 0 300
Crafts
Fingerprint Sensor Market Trends Driving Biometric Technology Adoption
Polaris Market Research today announced findings from its latest report, projecting the global...
By sakshi11 2026-09-28 11:21:15 0 232
Other
3D CAD Software Market Expected to Reach USD 26.6 Billion by 2036
August 20, 2026 — The global 3D CAD software market is estimated at USD...
By Alexa 2026-08-20 10:38:16 0 364
AC Mingle https://acmingle.com